Authors
Latest:
Dr Sands on Updated Efficacy Findings With Tarlatamab in Previously Treated SCLCJacob Sands, MD, discusses updated efficacy findings with tarlatamab treatment in previously treated patients with small cell lung cancer.
Latest:
Novel Treatment Approaches for SCLC and Future PerspectivesA panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.
Latest:
Noncovalent BTK Inhibitors in CLLRecommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.
Latest:
Optimizing the Treatment of CLL With Novel TherapiesOncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.
Latest:
Dr. Barrientos on Treatment Options for Patients With TP53 Mutations or 17p Deletions in CLLJacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.
Latest:
Dr. Barrientos on the Challenges in CLLJacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.
Latest:
Dr. Garcia on Future Expectations of Trials and Therapies in MyelofibrosisJacqueline S. Garcia, MD, discusses the future expectations of trials and therapies to improve outcomes in myelofibrosis.
Latest:
Can New Oncology Payment Programs Help Stabilize Medicare?Studies have raised doubts about the value Medicare and other payers are getting for the care they pay for, including in oncology. This has intensified the demand for new value-based care models such as the Merit-based Incentive Payment System and the Oncology Care Model.
Latest:
Key Takeaways and Clinical Pearls in the Treatment of R/R ALLThe key opinion leaders provide concluding insights and essential recommendations regarding the management of relapsed/refractory acute lymphoblastic leukemia.
Latest:
Minimally Invasive Esophagectomy Improves Outcomes, But Remains UnderutilizedSurgery remains the most effective curative treatment for esophageal cancer. Yet, many eligible patients do not undergo esophagectomy.
Latest:
Emerging Therapies for the Older Patient With Acute Lymphoblastic LeukemiaDr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.
Latest:
ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment LandscapeFollowing the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
Latest:
Dr. Kim on the Safety of Immune Checkpoint Inhibition in Surgical Patients With Lung CancerJae Y. Kim, MD, chief, Division of Thoracic Surgery, Department of Surgery, assistant professor, Department of Surgery, City of Hope, discusses the use of immune checkpoint inhibitors in surgical patients with lung cancer.
Latest:
The Art of Analogies in the ClinicTranslating medical nomenclature into language that is easily understood by patients can be difficult.
Latest:
Ars Medica: Soothing cancer patients through art therapyBefore Western medicine took root, therapies often tapped both the mind and body to promote healing.
Latest:
Dr. Micallef on NuQ Blood Tests in Prostate CancerJake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.
Latest:
Dr. Sehouli Discusses Unmet Needs in Ovarian CancerJalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses the unmet needs for patients with ovarian cancer.
Latest:
Dr. Abraham on Improving Access to Therapy With BiosimilarsJame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, and professor of medicine, Cleveland Clinic Lerner College of Medicine, discusses improving access to cancer therapy with biosimilars.
Latest:
Achieving Career Success in Academic OncologyAcademic oncologists have a critical role as opinion leaders and shape the future of cancer care by research and training future oncologists, residents, and medical students.
Latest:
Specialty Pharmacy: Status and Future DirectionWhen talking about specialty pharmacy, I am reminded of the famous words of Supreme Court Justice Potter Stewart as he ruled on a 1964 obscenity case.
Latest:
Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal CancerStudies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer
Latest:
Dr Yu discusses the ARCAD Nomogram in a Real-World CRC PopulationJames Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.
Latest:
Dr. Battiste on Biomarkers in GlioblastomaJames Battiste, MD, PhD, assistant professor at the University of Oklahoma department of neurology and researcher at Stephenson Cancer Center, discusses research in glioblastoma (GBM).
Latest:
Dr. Blachly on ctDNA as a Biomarker in Hairy Cell LeukemiaJames Blachly, MD, discusses the role of circulating tumor DNA as a biomarker for patients with hairy cell leukemia.
Latest:
Oncologists and HospiceOncologists need to learn that it is possible, and indeed preferable, to have very early discussions about end-of-life choice.
Latest:
Dr. Yang Discusses the Future of Lung Cancer TreatmentJames CH Yang, MD, PhD, from the National Taiwan University Hospital, discusses the future of lung cancer treatment.
Latest:
Dr. Yao on Health-Related QOL in Patients With Neuroendocrine TumorsJames C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).
